SANOCHEMIA Pharmazeutika AG

Grant of patent for Vidon® Photodynamic Diagnosis of Bladder Cancer in the USA

Business news for the stock market

Wien (pta006/13.01.2017/08:15) - Sanochemia Pharmazeutika AG, Vienna (ISIN AT0000776307 ISIN DE000A1G7JQ9), announces that the United States Patent and Trademark Office has issued "Notice of Allowance" for Vidon® in Photodynamic Diagnosis (PDD) of bladder cancer.

Vidon® (PVP-Hypericin) is one of Sanochemia ` s promising pipeline products and is being developed as a game changing technology in the management of bladder cancer. The patent covers the method for improved detection of bladder cancer with Sanochemia's developed PVP-Hypericin formulation. The U.S. patent will protect Vidon® until 2035.

"The Notice of Allowance for the US application of Vidon® for PDD is an important milestone for Sanochemia to secure the long-term value of Vidon®", said Dr. Christina Abrahamsberg, CSO of Sanochemia Pharmazeutika AG.
-------------------------------------------------------------------------------------------------------
Bladder cancer is the most common malignancy of the urinary tract. Approximately 75% of initially diagnosed bladder cancers are non-muscle invasive tumors, which means that the tumor is restricted to the mucosa. In 30-80% of the patients, recurrences occur, requiring repeated surgeries. About 45% of bladder cancers will progresses to a muscle-invasive bladder carcinoma.

Early detection, timely and appropriate treatment are therefore essential factors for improving the prognosis of urinary bladder carcinoma patients.

Photodynamic diagnosis (PDD) is a method for better visualization and hence earlier detection of urinary bladder tumors. PDD is more sensitive than standard white-light cystoscopy in the detection of malignant lesions. PDD is based on selective accumulation of a photosensitizer in malignant cells.

Vidon® is developed by Sanochemia Pharmazeutika AG as a diagnostic option for patients with non-muscle invasive bladder cancer. A PDD using Vidon® makes it easier for the urologist to find malignant tumors. Vidon® shows significantly improved tumor detection and an excellent safety profile in clinical trials.

(end)

emitter: SANOCHEMIA Pharmazeutika AG
address: Boltzmanngasse 11, 1090 Wien
country: Austria
contact person: Bettina Zuccato
phone: [phone]
e-mail: [e-mail]
website: www.sanochemia.at

ISIN(s): AT0000776307 (share), DE000A1G7JQ9 (bond)
stock exchanges: entry standard in Frankfurt, free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf; MTF - Mid Market in Vienna; open market in Berlin

[ source: http://www.pressetext.com/news/20170113006 ]